JMP Securities analyst Constantine Davides lowered the firm’s price target on AMN Healthcare (AMN) to $47 from $57 and keeps an Outperform rating on the shares following Q3 results. Unfulfilled nurse and allied orders increased from 9% in the prior quarter to 14% currently, as advertised compensation rates are not attractive enough to entice potential travelers, JMP Securities told investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare price target lowered to $47 from $50 at Truist
- AMN Healthcare downgraded to Market Perform from Outperform at William Blair
- AMN Healthcare Reports Q3 2024 Financial Results
- AMN Healthcare reports Q3 adjusted EPS 61c, consensus 57c
- AMN Healthcare sees Q4 revenue $685M-$705M, consensus $667.95M